Cargando…
Effect of levosimendan treatment on length of hospital and intensive care stay in the REVIVE I study
Autores principales: | Johansson, S, Apajasalo, M, Sarapohja, T, Garratt, C |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2004
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4099675/ http://dx.doi.org/10.1186/cc2555 |
Ejemplares similares
-
Development of a comprehensive new endpoint for the evaluation of new treatments for acute decompensated heart failure: results with levosimendan in the REVIVE 1 study
por: Garratt, C, et al.
Publicado: (2004) -
A systematic review of intensive care length of stay indicators
por: Burry, L
Publicado: (2004) -
Study design of a mortality trial with intravenous levosimendan (the SURVIVE study) in patients with acutely decompensated heart failure
por: Mebazaa, A, et al.
Publicado: (2004) -
Assessment of mortality post-ICU associated to the intensive care unit length of stay
por: Gómez Triana, F, et al.
Publicado: (2015) -
Haemoglobin concentration on admission to intensive care influences hospital mortality rates and length of stay: a retrospective study
por: Adams, M, et al.
Publicado: (2013)